[Labile blood product traceability: definition, regulation, evaluation, and perspectives]

Area of Science:

• Blood banking and transfusion medicine
• Public health policy
• Healthcare systems management

Background:

• Blood product traceability is a cornerstone of hemovigilance and transfusion safety.
• French Law no 94-68 of January 24, 1994, provides the legal framework for traceability.
• Understanding the existing system's structure and key participants is vital.

Purpose of the Study:

• To discuss the structures and main actors within the blood product traceability system.
• To evaluate the feasibility and adaptability of the current traceability system.
• To highlight the necessity of an evaluation process for system monitoring and improvement.

Main Methods:

• Review of French Law no 94-68 concerning blood product traceability.
• Analysis of the structural components of the traceability system.
• Identification and discussion of the primary stakeholders involved in hemovigilance.

Main Results:

• The blood product traceability system, based on specific legislation, has been evaluated.
• The system demonstrates feasibility and adaptability in practice.
• Key actors and structural elements of the traceability framework have been identified.

Conclusions:

• The implemented blood product traceability system is both feasible and adaptable.
• An ongoing evaluation process is essential for assessing system performance.
• Continuous evaluation helps in detecting and preventing potential deficiencies in hemovigilance.